OncoDNA
OncoDNA is a theranostic and genomic company focused on precision medicine in oncology, offering biomarker tests including OncoDEEP for precision medicine profiling, OncoSELECT for liquid biopsy monitoring, and OncoTRACE for treatment response tracking. The company provides comprehensive molecular profiling services that analyze tumor tissue and blood samples to identify actionable biomarkers, helping oncologists…
Funding snapshot
About
OncoDNA is a theranostic and genomic company focused on precision medicine in oncology, offering biomarker tests including OncoDEEP for precision medicine profiling, OncoSELECT for liquid biopsy monitoring, and OncoTRACE for treatment response tracking. The company provides comprehensive molecular profiling services that analyze tumor tissue and blood samples to identify actionable biomarkers, helping oncologists select targeted therapies and immunotherapies for cancer patients. OncoDNA's platform integrates genomic sequencing, bioinformatics analysis, and clinical interpretation to deliver personalized treatment recommendations based on the latest scientific evidence and clinical trial data. The company serves oncologists, cancer centers, and pharmaceutical companies conducting precision oncology research. Founded in 2012 and headquartered in Charleroi, Belgium, OncoDNA has raised approximately $44.5 million in Series C funding from investors including SFPI, SRIW, Sambrinvest, Vesalius Biocapital III, and Ackermans & van Haaren.
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified > Precision Medicine,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine,
Life Sciences Platforms and Tools > Research Reagents and Kits > Genomics
Founders & team highlights
Serial Founder
Team background
Top Rated Teams > Serial Entrepreneur
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.